341 related articles for article (PubMed ID: 31285372)
1. Use of Circulating Tumor DNA for Cancer Immunotherapy.
Snyder A; Morrissey MP; Hellmann MD
Clin Cancer Res; 2019 Dec; 25(23):6909-6915. PubMed ID: 31285372
[TBL] [Abstract][Full Text] [Related]
2. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
3. Current and Future Clinical Applications of ctDNA in Immuno-Oncology.
Stadler JC; Belloum Y; Deitert B; Sementsov M; Heidrich I; Gebhardt C; Keller L; Pantel K
Cancer Res; 2022 Feb; 82(3):349-358. PubMed ID: 34815256
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
6. The Introduction and Clinical Application of Cell-Free Tumor DNA.
Li J; Liu R; Huang C; Chen S; Xu M
Methods Mol Biol; 2018; 1754():45-65. PubMed ID: 29536437
[TBL] [Abstract][Full Text] [Related]
7. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy.
Sivapalan L; Murray JC; Canzoniero JV; Landon B; Jackson J; Scott S; Lam V; Levy BP; Sausen M; Anagnostou V
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657818
[TBL] [Abstract][Full Text] [Related]
9. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
[No Abstract] [Full Text] [Related]
10. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
[TBL] [Abstract][Full Text] [Related]
11. Circulating cell-free tumor DNA analysis in pediatric cancers.
Andersson D; Fagman H; Dalin MG; Ståhlberg A
Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
[TBL] [Abstract][Full Text] [Related]
12. Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.
Liu Z; Han Y; Dang Q; Xu H; Zhang Y; Duo M; Lv J; Li H; Kong Y; Han X
Int Immunopharmacol; 2022 Oct; 111():109173. PubMed ID: 35998502
[TBL] [Abstract][Full Text] [Related]
13. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.
Rossi G; Ignatiadis M
Cancer Res; 2019 Jun; 79(11):2798-2804. PubMed ID: 31109952
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet BY; Esfahani MS; Moding EJ; Hamilton EG; Chabon JJ; Rizvi H; Steen CB; Chaudhuri AA; Liu CL; Hui AB; Almanza D; Stehr H; Gojenola L; Bonilla RF; Jin MC; Jeon YJ; Tseng D; Liu C; Merghoub T; Neal JW; Wakelee HA; Padda SK; Ramchandran KJ; Das M; Plodkowski AJ; Yoo C; Chen EL; Ko RB; Newman AM; Hellmann MD; Alizadeh AA; Diehn M
Cell; 2020 Oct; 183(2):363-376.e13. PubMed ID: 33007267
[TBL] [Abstract][Full Text] [Related]
15. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
Koessler T; Addeo A; Nouspikel T
Adv Clin Chem; 2019; 89():131-188. PubMed ID: 30797468
[TBL] [Abstract][Full Text] [Related]
16. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.
Abbou SD; Shulman DS; DuBois SG; Crompton BD
Pediatr Blood Cancer; 2019 May; 66(5):e27595. PubMed ID: 30614191
[TBL] [Abstract][Full Text] [Related]
17. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
18. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
19. Enrichment and Analysis of ctDNA.
Gilson P
Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
[TBL] [Abstract][Full Text] [Related]
20. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
